Biofourmis, a Boston-based global leader in virtual care and digital therapeutics, announced July 29 the company’s BiovitalsHF solution is the first-ever heart failure digital therapeutic to receive a Breakthrough Device designation from the U.S. Food and Drug Administration.

A large organization of internal medicine physicians said adults with type 2 diabetes can aim for an easier-to-achieve blood sugar target than what has been used to guide treatment in the past.